All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MDS Hub

MDS Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
Add bookmark

The role of the tumor microenvironment on CAR T-cell therapy in B-cell lymphoma

Here, we summarize the review article by Cai et al., on the mechanisms by which the TME influences CAR T-cell efficacy in B-cell lymphoma, as well as the emerging...

Dec 7, 2023
Add bookmark

Phase III SELENE trial: efficacy and safety of ibrutinib plus BR/R-CHOP in R/R FL or MZL

Here, we summarize key efficacy and safety data from the randomized phase III SELENE trial investigating ibrutinib plus BR or R-CHOP compared with placebo in...

Dec 5, 2023
Add bookmark

FDA approves pirtobrutinib for patients with relapsed/refractory CLL/SLL

Pirtobrutinib has been approved by the U.S. FDA for the treatment of patients with relapsed/refractory CLL or SLL, based on results from the phase I/II BRUIN trial.

Dec 5, 2023
Add bookmark

ASH 2023: Top abstracts in lymphoma and CLL

To help navigate the exciting content being presented at the 65th ASH Annual Meeting and Exposition, the Lymphoma Hub Steering Committee have provided their recommendations for the top abstracts to look out...

Dec 5, 2023
Gilles Salles

"The Lymphoma Hub allows you to navigate the most relevant and up-to-date information in lymphoma and CLL. From recently published papers to on-site interviews, we aim to deliver valuable data to all physicians practicing hemato-oncology.."

Gilles Salles

"The Lymphoma Hub allows you to navigate the most relevant and up-to-date information in lymphoma and CLL. From recently published papers to on-site interviews, we aim to deliver valuable data to all physicians practicing hemato-oncology.."

Your opinion matters

Which treatment do you select for patients with follicular lymphoma after multiple relapses?
0 votes - 6 days left ...

Congresses

view more

Therapeutics

view more

Most Read

Supportive care

view more

Treatment of older patients with lymphoma and CLL

view more

Most Viewed